About KyungDong Pharma
KyungDong Pharma is a company based in Seoul (South Korea) founded in 1975. It operates as a Direct-to-Consumer (D2C) and Reseller / Distribution. The company has 383 employees. KyungDong Pharma offers products and services including Dapajin SM Sustained-Release Tablets, Telkadin, and Geunareun. KyungDong Pharma operates in a competitive market with competitors including Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
- Headquarter Seoul, South Korea
- Employees 383
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website kdpharma.co.kr
- Social Facebook Instagram
- Legal Name Kyung Dong Pharmaceutical Co., Ltd
- Annual Revenue$135.9 M (USD)1.2as on Dec 31, 2025
- Net Profit$5.91 M (USD)55.93as on Dec 31, 2025
- EBITDA$7.85 M (USD)41.03as on Dec 31, 2025
- Employee Count383
Products & Services of KyungDong Pharma
KyungDong Pharma offers a comprehensive portfolio of products and services, including Dapajin SM Sustained-Release Tablets, Telkadin, and Geunareun.
Used for treating type 2 diabetes effectively in patients.
ARB medication for hypertension with convenient blister packaging.
Pain reliever offered for general public health support.
IPO & Listings of KyungDong Pharma
KyungDong Pharma is a publicly listed company on the KRX with ticker symbol 011040 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Dec 1992
- Listed onKRX: 11040
- Listed entityKYUNG DONG PHARMACEUTICAL Co., Ltd
- Exchange sectorHealth technology
- ISINKR7011040003
- Share price5,080.00 KRW (+0.4% on the day) · 2026-10-08
- Market capitalisation136,958,675,079.00 KRW
- Price to earnings7.8
- EPS (diluted, trailing year)648.16 KRW
- Dividend yield5.91%
- Volume (last session)14,367
Financials of KyungDong Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 196.27B KRW | 8.53B KRW | 11.34B KRW |
| 2024 | 193.94B KRW | 5.47B KRW | 8.04B KRW |
| 2023 | 162.67B KRW | -20.71B KRW | -19.11B KRW |
| 2022 | 182.72B KRW | 12.16B KRW | 15.02B KRW |
| 2021 | 177.61B KRW | 12.67B KRW | 22.77B KRW |
Detailed financial statements for KyungDong Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of KyungDong Pharma
KyungDong Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, AbbVie, Lilly, Roche and Novo Nordisk, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| novonordisk.com | 1923 | Bagsvaerd, Denmark | $145,000 | 29,288 | Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| astrazeneca.com | 1913 | Cambridge, United Kingdom | – | 83,100 | Pharmaceutical and biologics products are developed and distributed worldwide. | |
| bausch.com | 1853 | Bridgewater, United States | – | 1,681 | Ophthalmic pharmaceuticals and instruments are developed for eye care. | |
| amgen.com | 1980 | Thousand Oaks, United States | – | 26,700 | Developer of pharmaceutical products for treating multiple diseases |
Detailed competitors of KyungDong Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of KyungDong Pharma
The website of KyungDong Pharma (kdpharma.co.kr) receives about 11.5K visits a month and ranks #1,661,256 among all websites worldwide, #2,234 in Biotechnology and Pharmaceuticals.
- Monthly visits11.5K
▼ 21% vs previous month
- Unique visitors7.3K
per month
- Global rank#1,661,256
among all websites
- Category rank#2,234
Health · Biotechnology and Pharmaceuticals
- Bounce rate50%
- Pages per visit1.8
- Average visit27 sec
- DevicesDesktop 17% · Mobile 83%
Websites whose visitors overlap most with KyungDong Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| bukwang.co.kr | 100% | 142.7K | #395,152 | View details | |
| daewonpharm.com | 88% | 95.4K | – | View details | |
yagiyagi.kr | yagiyagi.kr | 72% | – | #1,849,329 | – |
doumdoc.com | doumdoc.com | 68% | – | #2,102,795 | – |
bktimes.net | bktimes.net | 58% | – | #936,072 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for KyungDong Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Kyungdong Pharma
Complete news archive for KyungDong Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to KyungDong Pharma
10 companies that operate in the same segment as KyungDong Pharma (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about KyungDong Pharma
KyungDong Pharma was founded in 1975.
KyungDong Pharma is headquartered in Seoul, South Korea.
KyungDong Pharma has 383 employees.
Annual revenue of KyungDong Pharma is $135.9M as on Dec 31, 2025.
KyungDong Pharma is involved in the development and production of pharmaceuticals, including prescription and over-the-counter medicines. The company operates in the healthcare sector, focusing on solutions for chronic conditions like diabetes and hypertension. Advanced manufacturing facilities and proprietary technologies are utilized to ensure high-quality products. Additionally, health supplements and quasi-drugs are offered to support public health. Research and development efforts are directed towards generics, improved new drugs, and active pharmaceutical ingredients. The commitment to lifelong health of the nation is emphasized through innovative solutions.
KyungDong Pharma's top competitors include Merck, Roivant Sciences and Amgen.
KyungDong Pharma offers Dapajin SM Sustained-Release Tablets, Telkadin, and Geunareun.
Yes, KyungDong Pharma is publicly traded on KRX under the ticker symbol 011040.
KyungDong Pharma operates through Kyungdong Pharm. Co., Ltd.